Top

23-12-2023 | Diabetic Cardiomyopathy | Original Article

MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model

Authors: Nan Wu, Caijie Shen, Jian Wang, Xiaomin Chen, Peng Zhong

Published in: Cardiovascular Drugs and Therapy

Abstract

Background

Diabetic cardiomyopathy (DCM) pathogenesis is a common complication of diabetes, but effective treatments remain limited. Mitochondrial-derived peptide MOTS-c has shown therapeutic promise in animal models of various heart diseases, but its efficacy in DCM is unknown. This study investigates the effects of MOTS-c treatment in a mouse model of type 1 diabetes-induced DCM.

Methods

Type 1 diabetes (T1DM) was induced in mice by streptozotocin (STZ) injection. After diabetes establishment, the mice were randomly dividend into two groups treated with or without MOTS-c peptide, which was administered subcutaneously by osmotic pump for 12 weeks. At the end of the experiment, cardiac function, histology, and molecular changes were determined.

Results

The results showed that diabetic mice exhibited significant cardiac dysfunction, dilatation, and adverse cardiac remodeling. MOTS-c treatment markedly ameliorated these diabetes-associated myocardial function and structure abnormalities. Additionally, MOTS-c reversed AMPK signaling deactivation and inhibited inflammation in the diabetic heart.

Conclusions

Our data demonstrated a protective effect of MOTS-c against diabetic cardiomyopathy potentially by activating the AMPK pathway and inhibiting inflammation. These findings demonstrate the therapeutic efficacy of MOTS-c for diabetic cardiomyopathy and warrant further investigation into its clinical potential.

Li Y, Ma J, Zhu H, et al. Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes. 2011;60(11):2985–94. https://doi.org/10.2337/db10-1333.CrossRefPubMedPubMedCentral

Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60(6):1770–8. https://doi.org/10.2337/db10-0351.CrossRefPubMedPubMedCentral

Wu S, Lu Q, Ding Y, et al. Hyperglycemia-driven inhibition of AMP-activated protein kinase α2 induces diabetic cardiomyopathy by promoting mitochondria-associated endoplasmic reticulum membranes in vivo. Circulation. 2019;139(16):1913–36. https://doi.org/10.1161/circulationaha.118.033552.CrossRefPubMedPubMedCentral

Yuan J, Wang M, Pan Y, et al. The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats. Sci Rep. 2021;11(1):20077. https://doi.org/10.1038/s41598-021-99568-3.CrossRefPubMedPubMedCentral

Zhong P, Peng J, Liu T, Ding HS. AAV9-mediated cardiac CNTF overexpression exacerbated adverse cardiac remodeling in streptozotocin-induced type 1 diabetic models. Cardiovasc Toxicol. 2022;22(1):88–96. https://doi.org/10.1007/s12012-021-09706-6.CrossRefPubMed

Zhong P, Zeng G, Lei C, et al. Ciliary neurotrophic factor overexpression protects the heart against pathological remodelling in angiotensin II-infused mice. Biochem Biophys Res Commun. 2021;547:15–22. https://doi.org/10.1016/j.bbrc.2021.01.111.CrossRefPubMed

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–54. https://doi.org/10.1016/j.cmet.2015.02.009.CrossRefPubMedPubMedCentral

Grubić Rotkvić P, Planinić Z, Liberati Pršo AM, et al. The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities. Int J Mol Sci. 2021;22(11). https://doi.org/10.3390/ijms22115973.

Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182–7. https://doi.org/10.1016/j.freeradbiomed.2016.05.015.CrossRefPubMedPubMedCentral

10.

Yan Z, Zhu S, Wang H, et al. MOTS-c inhibits osteolysis in the mouse calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res. 2019;147:104381. https://doi.org/10.1016/j.phrs.2019.104381.CrossRefPubMed

11.

Zhai D, Ye Z, Jiang Y, et al. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol. 2017;92:151–60. https://doi.org/10.1016/j.molimm.2017.10.017.CrossRefPubMed

12.

Li H, Ren K, Jiang T, Zhao GJ. MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-κB pathway. Int J Cardiol. 2018;268:40. https://doi.org/10.1016/j.ijcard.2018.03.031.CrossRefPubMed

13.

Shen C, Wang J, Feng M, et al. The mitochondrial-derived peptide MOTS-c attenuates oxidative stress injury and the inflammatory response of H9c2 cells through the Nrf2/ARE and NF-κB pathways. Cardiovasc Eng Technol. 2021. https://doi.org/10.1007/s13239-021-00589-w.

14.

Bairwa SC, Parajuli N, Dyck JR. The role of AMPK in cardiomyocyte health and survival. Biochim Biophys Acta. 2016;1862(12):2199–210. https://doi.org/10.1016/j.bbadis.2016.07.001.CrossRefPubMed

15.

Wang X, Wang Y, Antony V, Sun H, Liang G. Metabolism-associated molecular patterns (MAMPs). Trends Endocrinol Metab. 2020;31(10):712–24. https://doi.org/10.1016/j.tem.2020.07.001.CrossRefPubMed

16.

Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes. 2008;57(11):3090–8. https://doi.org/10.2337/db08-0564.CrossRefPubMedPubMedCentral

17.

Ma J, Chadban SJ, Zhao CY, et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One. 2014;9(5):e97985. https://doi.org/10.1371/journal.pone.0097985.CrossRefPubMedPubMedCentral

18.

Lin M, Yiu WH, Wu HJ, et al. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):86–102. https://doi.org/10.1681/asn.2010111210.CrossRefPubMed

19.

Zhang Y, Peng T, Zhu H, et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of toll-like receptor-4. J Transl Med. 2010;8:133. https://doi.org/10.1186/1479-5876-8-133.CrossRefPubMedPubMedCentral

20.

Tao A, Song J, Lan T, et al. Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: role of HMGB1/TLR4/IL-33 axis. Biochim Biophys Acta. 2015;1852(10 Pt A):2075–85. https://doi.org/10.1016/j.bbadis.2015.07.015.CrossRefPubMed

21.

Wu J, Xiao D, Yu K, et al. The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy. Acta Biochim Biophys Sin (Shanghai). 2023;55(2):285–94. https://doi.org/10.3724/abbs.2023006.CrossRefPubMed

22.

Jiang J, Chang X, Nie Y, et al. Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis. Eur J Pharmacol. 2023;939:175469. https://doi.org/10.1016/j.ejphar.2022.175469.CrossRefPubMed

23.

Bess E, Fisslthaler B, Frömel T, Fleming I. Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells. PLoS One. 2011;6(6):e20848. https://doi.org/10.1371/journal.pone.0020848.CrossRefPubMedPubMedCentral

24.

Rutherford C, Speirs C, Williams JJ, et al. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci Signal. 2016;9(453):ra109. https://doi.org/10.1126/scisignal.aaf8566.CrossRefPubMed

25.

Schulz E, Dopheide J, Schuhmacher S, et al. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation. 2008;118(13):1347–57. https://doi.org/10.1161/circulationaha.108.784298.CrossRefPubMedPubMedCentral

26.

Mancini SJ, White AD, Bijland S, et al. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol Cell Endocrinol. 2017;440:44–56. https://doi.org/10.1016/j.mce.2016.11.010.CrossRefPubMedPubMedCentral

Title: MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model
Authors: Nan Wu
Caijie Shen
Jian Wang
Xiaomin Chen
Peng Zhong
Publication date: 23-12-2023
Publisher: Springer US
Keyword: Diabetic Cardiomyopathy
Published in: Cardiovascular Drugs and Therapy
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-023-07540-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page